In a recent analysis, U.S. healthcare payers evaluated the financial implications of combining adagrasib with cetuximab for treating colorectal cancer patients harboring the KRAS G12C mutation. The study sheds light on whether the combination therapy offers economic advantages over the standard adagrasib monotherapy.
Methodology of Economic Evaluation
Researchers utilized a three-state partitioned survival model to assess the cost-effectiveness of the combination treatment versus monotherapy. By extracting Kaplan-Meier survival curves from clinical trials, they applied a Log-Logistic model to extrapolate long-term overall survival (OS) and progression-free survival (PFS) beyond the trial period.
Cost Analysis and Quality of Life Metrics
The financial analysis revealed that administering adagrasib combined with cetuximab incurs an estimated cost of $290,645, significantly higher than the $188,837 for adagrasib alone. Additionally, the utility measurement indicated a decrease in quality-adjusted life years (QALYs) for the combination therapy, with patients achieving 1.094 QALYs compared to 1.359 QALYs with monotherapy.
Key Insights:
- The combination therapy presents a higher financial burden without delivering improved patient outcomes.
- Monotherapy remains a more economically viable option for treating KRAS G12C mutated colorectal cancer.
- Healthcare payers may need to reconsider coverage strategies for combination treatments based on these findings.
The incremental cost-effectiveness ratio (ICER) stood at -384,674.32 USD/QALY, indicating that the combination of adagrasib and cetuximab does not provide a cost-effectiveness advantage over monotherapy for this patient population.
Given these results, healthcare providers and policymakers should prioritize cost-effective treatment strategies that maximize patient benefits while managing expenses. Further research may explore alternative combination therapies or identify patient subgroups that could benefit economically from combined treatments.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
